QNRX
Quoin Pharmaceuticals, Ltd. (NASDAQ)
Healthcare — Biotechnology
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Price History
Fundamentals
| Market Cap | $9.46M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.62 |
| EPS (TTM) | $-10.07 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -231.18% |
| Debt/Equity | 24.78 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $21.40 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 46.4 |
| Beta | 1.68 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $41.80 |
| 52-Week Low | $3.25 |
| 50-Day Avg | $5.15 |
| 200-Day Avg | $9.27 |
| Avg Volume | 247.2K |
| Volume | 57.7K |
Performance Analysis
BULLISHQNRX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:28 UTC
Back to Screener Export Report